Latest Aetna Update- April 2025 Source Aetna No Longer Requiring Precertification (Effective March 1, 2025) BRCA Genetic Testing (CPT Code 81433) Evrysdi (risdiplam) J8499 Require Precertification Effective March 14, 2025 Ziihera (zanidatamab-hrii, J3490, J3590, C9399, J9999) Bizengri (zenocutuzumab-zbco, J3490, J3590, C9399, J9999) Unloxcyt (cosibelimab-ipdl, J3490, J3590, C9399, J9999) Effective April 1, 2025 Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) J3490, J3590, C9399, J9999 Medicare only: Axtle (pemetrexed, avyxa) J9292 Pemrydi RTU (pemetrexed) J9324 Effective April 4, 2025 Jubbonti (denosumab-bbdz) J3490, J3590, C9399 Wyost (denosumab-bbdz) J3490, J3590, C9399 Effective April 18, 2025 Datroway (datopotamab deruxtecan-dlnk, J3490, J3590, C9399, J9999) precertification includes site of care Ryoncil (remestemcel-L, J3490, J3590, C9399, J9999) Submitting Precertification Requests Submit requests at least 2 weeks in advance , including the actual date of service
After evaluating your treatment area, Dr
Serino, M
New research in Atherosclerosis Plus highlights a powerful, low-cost diagnostic flag with routinely tested biomarkers: the C-reactive proteintriglycerideglucose index CTI
GCLC-KO mice showed activation of C1q, which triggers engulfment of neurons by microglia, and disease-associated-microglia (DAM), suggesting that activation of microglia is linked to the neuronal loss
